The trial is taking place at:

Dignity Health | Comprehensive Blood and Cancer Center

Veeva-enabled site

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Sanofi

Status and phase

Active, not recruiting

Phase 2

Conditions

Breast Cancer Metastatic

Treatments

Drug: Tamoxifen

Drug: Anastrozole

Drug: Letrozole

Drug: Fulvestrant

Drug: Amcenestrant

Drug: Exemestane

Study type

Interventional

Funder types

Industry

Identifiers

NCT04059484

U1111-1217-2774 (Other Identifier)

2018-004593-98 (EudraCT Number)

ACT16105

Details and patient eligibility

About

Primary Objective:

To determine whether amcenestrant per overall survival (os) improves progression free survival (PFS) when compared with an endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer

Secondary Objectives:

To compare the overall survival in the 2 treatment arms
To assess the objective response rate in the 2 treatment arms
To evaluate the disease control rate in the 2 treatment arms
To evaluate the clinical benefit rate in the 2 treatment arms
To evaluate the duration of response in the 2 treatment arms
To evaluate the PFS according to the estrogen receptor 1 gene (ESR1) mutation status in the 2 treatment arms
To evaluate the pharmacokinetics of amcenestrant as single agent
To evaluate health-related quality of life in the 2 treatment arms
To compare the overall safety profile in the 2 treatment arms

Full description

The duration of the study for an individual participant will include a period to assess eligibility (screening period) of up to 4 weeks (28 days), a treatment period of at least 1 cycle (28 days of study treatment), and an end of treatment (EOT) visit at least 30 days (or until the participant receive another anticancer therapy, whichever is earlier) following the last administration of study treatment. Study treatment may continue until precluded by unacceptable toxicity, disease progression, death or upon participant's request to stop treatment, or Investigator decision, whichever occurs first.

An extension of recruitment for Chinese participants is planned in this study: After completion of randomization in the global part of the study, randomization will continue in China until approximately 90 Chinese participants are randomized.

Enrollment

367 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria :

18 years or older.
Histological or cytological diagnosis of adenocarcinoma of the breast.
Locally advanced not amenable to radiation therapy or surgery in a curative intent, and/or metastatic disease.
Estrogen receptor(ER) positive status.
Human epidermal growth factor receptor 2 negative status.
Participants must have received no more than 1 prior chemotherapeutic or 1 targeted therapy regimen for advanced/metastatic disease.
In the main study, a prior treatment with a Cyclin-dependent kinase 4 and 6(CDK 4/6) inhibitor is mandatory if this treatment is approved and can be reimbursed for this participant. The percentage of participants without previous CDK 4/6 inhibitor will be capped to 20%. In the Chinese extension cohort, previous treatment with a CDK 4/6 inhibitor will not be mandatory, and there will be no limitation to the number of participants naïve to CDK4/6 inhibitor.
Participants must present a secondary endocrine resistance to endocrine therapy defined as: progression while on endocrine therapy after at least 6 months of treatment for advanced breast cancer, or relapse while on adjuvant endocrine therapy but after the first 2 years, or with a relapse within 12 months after completing adjuvant endocrine therapy.
Male or Female.

Exclusion criteria:

Eastern Cooperative Oncology Group performance status =>2.
Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of amcenestrant. Participants unable to swallow normally and to take capsules.
Participant with any other cancer. Adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or any other cancer from which the participant has been disease free for greater than 3 years are allowed.
Severe uncontrolled systemic disease at screening .
Participants with known brain metastases that are untreated, symptomatic or require therapy to control symptoms.
Prior treatment with mammalian target of rapamycin inhibitors or any other selective estrogen receptor degrader(SERD) compound, except fulvestrant if stopped for at least 3 months before randomization.
Treatment with drugs that have the potential to inhibit Uridine'5 Diphospho-Glucuronosyl Transferase(UGT) less than 2 weeks before randomization.
Treatment with strong Cytochrome P450 (CYP)3A inducers within 2 weeks before randomization.
Ongoing treatment with drugs that are sensitive substrate of organic anion transporting polypeptide 1B1/B3(OATP1B1/B3) (asunaprevir, atorvastatin, bosentan, danoprevir, fexofenadine, glyburide, nateglinide, pitavastatin, pravastatin, replaglinide, rosuvastatin, and simvastatin acid).
Treatment with anticancer agents (including investigational drugs) less than 3 weeks before randomization.
Inadequate hematological, coagulation, renal and liver functions.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

367 participants in 2 patient groups

Amcenestrant

Experimental group

Description:

Daily amcenestrant dose administered orally under fed or fast condition

Treatment:

Drug: Amcenestrant

Fulvestrant/Aromatase inhibitors/Estrogen receptor modulator

Active Comparator group